The Sorry State of Indian Surrogates
By Gina Maranto, <i>Biopolitical Times</i> guest contributor
| 08. 06. 2013
The surrogacy industry in India is both booming and changing. A new 168-page report from the Centre for Social Research, a women’s advocacy group based in New Delhi, finds that the industry appears to be shifting from towns like Anand and Amritsar to the megacities Mumbai and New Delhi, which are more easily accessible to international travelers and have higher quality health care facilities. Surrogate Motherhood: Ethical or Commercial documents a range of disturbing conditions: Although the government has guidelines for assisted reproduction clinics, regulation continues to be spotty and current law affords scant protection to the poor, largely uneducated women who are being drafted to serve as incubators, or to the resulting children handed over to primarily foreign clients.
Foreign scholars and journalists have probed the Indian surrogacy business for some years. Within the country, groups like the Sama Resource Group for Women and Health have drawn attention to the broader practices of ART clinics, as in their 2008 publication Cheap and Best, which puts the industry in the context of global medical tourism and examines the...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...